STOCKS TELEGRAPH

Tag: Cerevel Therapeutics Stock

  • What Sparked Rise In Cerevel (CERE) Amid Insider Selling

    What Sparked Rise In Cerevel (CERE) Amid Insider Selling

    Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) witnessed a noteworthy ascent of 11.37%, reaching $41.13 during the latest trading session on the US stock charts. Despite reports of insider selling activities, the surge in Cerevel stock was primarily catalyzed by a takeover bid.

    In a filing submitted to the Securities and Exchange Commission (SEC) last Thursday, Akamine Scott, the Chief Legal Officer of Cerevel (CERE), divested 17,500 shares of CERE. The transaction, conducted at an average selling price of $38.185, yielded gross proceeds totaling $676,200.

    CERE made a significant announcement yesterday, unveiling a definitive agreement with AbbVie Inc. According to the terms of the agreement, AbbVie will acquire Cerevel Therapeutics, encompassing its robust neuroscience pipeline with multiple clinical-stage assets. The acquisition extends to CERE’s preclinical candidates, exhibiting potential applications in various diseases, including schizophrenia, Parkinson’s disease (PD), and mood disorders.

    This strategic move complements AbbVie’s existing neuroscience portfolio, introducing a diverse array of potentially best-in-class assets that may revolutionize standards of care in psychiatric and neurological disorders with substantial unmet needs. One of Cerevel’s notable late-stage drugs, emraclidine, a positive allosteric modulator of the muscarinic M4 receptor, has demonstrated promise as a next-generation antipsychotic for treating schizophrenia, evidenced by positive Phase 1b results.

    Emraclidine is currently undergoing Phase 2 trials, offering potential benefits in Alzheimer’s disease and PD. The company’s portfolio also includes tavapadon for Parkinson’s (Phase 3), CVL-354 (Phase 1) for major depressive disorder, and darigabat (Phase 2) for treatment-resistant epilepsy and panic disorder. These assets align seamlessly with AbbVie’s neuroscience priorities, presenting opportunities for advancements across various therapeutic domains.

    As per the transaction terms, AbbVie is set to acquire all outstanding shares of CERE at a rate of $45.00 per share in cash. This transaction places the total equity value of Cerevel at approximately $8.7 billion. Both companies’ boards of directors have greenlit the transaction, which is slated to conclude in mid-2024, contingent upon Cerevel shareholder approval, regulatory clearances, and adherence to customary closing conditions.

  • How Does The Cerevel (CERE) Stock Price Increase By 52% Premarket?

    How Does The Cerevel (CERE) Stock Price Increase By 52% Premarket?

    The share price of Cerevel Therapeutics Holdings Inc. (CERE) rose 52.35% to trade at $19.15 at last check in premarket trading today. Cerevel stock closed on Monday at $12.57, down 3.01% from its previous close of $12.96. Volume of CERE stock traded was 0.35 million shares, which was higher than the average volume over the last three months, 302.67K shares. During the trading session, the CERE stock oscillated between $12.50 and $13.25.

    CERE had an earnings-per-share ratio of -2.41. Over the past five sessions, CERE has lost -8.78% of its value. On a month-to-month basis, CERE has lost -24.19% of its value. With a 50-day moving average of $13.85 CERE stock is above its 200-day moving average of $13.59. A RSI of 39.76 is currently being displayed on the CERE stock. After the topline results of a clinical trial, CERE stock has surged.

    The trial was held for what purpose?

    Cerevel’s goal is to uncover the mysteries of the brain with the goal of treating neurological diseases. A targeted neuroscience approach is used by CERE in its efforts to treat diseases combining expertise in neurocircuitry and receptor selectivity. CERE’s pipeline consists of five clinical-stage investigational therapies and several pre-clinical compounds that may be used to treat a variety of neurological diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorders. CERE has its headquarters in Cambridge, Mass., and is actively researching new technology modalities through internal initiatives, external collaborations, or possible acquisitions.

    Cerevel today announced positive results from its Phase 1b clinical trial involving CVL-231, a muscarinic M4-selective positive allosteric modulator (PAM).

    • A 6 week period of continuous dosing of CVL-231 and a placebo showed similar discontinuation rates: 22% each. In summary, CERE’s CVL-231 was well tolerated by trial participants.
    • In addition, both the daily dose of 30 mg and the twice-daily dose of 20 mg demonstrated antipsychotic activity with overall well-tolerated profiles when compared to placebo.
    • The positive and negative syndrome scale (PANSS) total score decreased from baseline by 19.5 points and points for the placebo group decreased by 12.7 points, both statistically significant and clinically meaningful reductions.
    • The PANSS total score decreased by 17.9 points in the CERE group compared with the placebo group after taking 20 mg twice a day of CVL-231.

    What CERE plans to do next?

    In light of these encouraging results, Cerevel (CERE) is confident that a targeted muscarinic therapy that targets the M4 receptor can provide clinically meaningful benefits in schizophrenia treatment. CERE is going a long way towards unraveling how the muscarinic pathway can best be leveraged to better treat schizophrenia, in part by developing a drug that is several hundred times more selective for M4 receptors than M1, M2, M3, and M5.